Immatics Biotechnologies GmbH

Closed (deSPAC)

Biotechnology company developing T-cell based cancer immunotherapies

What it is: A private company in biotechnology company developing t-cell based cancer immunotherapies preparing to list via a SPAC merger. Full profile in progress.
What it’s doing now: Merging with ARYA SCIENCES ACQUISITION CORP. (ARYA) — closed (despac), announced Mar 18, 2020.
What you should know: Data is still being assembled for this company — what is shown below is everything we have verified so far.

Profile in progress — we only publish what we can verify in filings, and for this company that work isn’t finished. Identity and deal facts above are current; business detail, financials and peers will appear as the filings are parsed.

The deal it’s entering

Immatics Biotechnologies GmbH is merging with ARYA SCIENCES ACQUISITION CORP. (ARYA) currently marked Closed (deSPAC).

Headline equity value	—
Post-close ticker	IMTX

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Immatics Biotechnologies GmbH going public?

Immatics Biotechnologies GmbH has an approved merger with the SPAC ARYA SCIENCES ACQUISITION CORP. (ARYA), announced Mar 18, 2020. The combined company expects to trade as IMTX. Deal status: Closed (deSPAC).

Does Immatics Biotechnologies GmbH have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.